Non Cystic Fibrosis Bronchiectasis Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies

DelveInsight's, "Noncystic fibrosis bronchiectasis Pipeline Insight, 2025" report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Noncystic fibrosis bronchiectasis pipeline landscape. It covers the Non Cystic Fibrosis Bronchiectasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Non Cystic Fibrosis Bronchiectasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Non Cystic Fibrosis Bronchiectasis Treatment Landscape @ Non Cystic Fibrosis Bronchiectasis Pipeline Outlook [https://www.delveinsight.com/sample-request/non-cystic-fibrosis-bronchiectasis-ncfb-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Non Cystic Fibrosis Bronchiectasis Pipeline Report

* On 17 August 2025, Verona Pharma plc announced a study is a randomized, double-blind, placebo-controlled study designed to assess the efficacy and safety of ensifentrine inhalation suspension (3 mg) delivered twice daily via standard jet nebulizer over at least 24 weeks, compared to placebo, in subjects with non-cystic fibrosis bronchiectasis (NCFBE).
* DelveInsight's Non Cystic Fibrosis Bronchiectasis pipeline report depicts a robust space with 15+ active players working to develop 15+ pipeline therapies for Non Cystic Fibrosis Bronchiectasis treatment.
* The leading Non Cystic Fibrosis Bronchiectasis Companies such as Zambon SpA, AstraZeneca, Insmed Incorporated, NovaBiotics, Haisco Pharmaceutical Group, Armata Pharmaceuticals, Chiesi Farmaceutici, CSL Behring and others.
* Promising Non Cystic Fibrosis Bronchiectasis Pipeline Therapies such as Nebulized Ensifentrine Suspension; 3 mg, HSK31858, ARINA-1, Brensocatib 10 mg, RESP302, BAY85-8501 and others.

Stay informed about the cutting-edge advancements in Non Cystic Fibrosis Bronchiectasis treatments. Download for updates and be a part of the revolution in Respiratory Diseases Care @ Non Cystic Fibrosis Bronchiectasis Clinical Trials Assessment [https://www.delveinsight.com/sample-request/non-cystic-fibrosis-bronchiectasis-ncfb-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Non Cystic Fibrosis Bronchiectasis Emerging Drugs Profile

* Brensocatib: Insmed Incorporated

Brensocatib (INS1007 or AZD7986) is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1). DPP1 is an enzyme responsible for activating neutrophil serine proteases (NSPs), such as neutrophil elastase, in neutrophils when they are formed in the bone marrow. Neutrophils are the most common type of white blood cell and play an essential role in pathogen destruction and inflammatory mediation. Brensocatib may decrease the damaging effects of inflammatory diseases such as bronchiectasis by inhibiting DPP1 and its activation of NSPs. Insmed acquired the license for the treatment from AstraZeneca in 2016. Currently, the drug is in Phase III stage of its clinical trial evaluation for the treatment of Noncystic fibrosis bronchiectasis.

* HSK31858: Haisco Pharmaceutical Group Co., Ltd.

HSK31858 tablet is an oral, potent, and highly selective dipeptidyl peptidase 1 (DPP1) small molecule inhibitor independently developed by the Haisco Pharmaceutical. The main mechanism of action is that inhibiting DPP1 can inhibit the activation of neutrophils and the release of neutrophils to the circulatory system by inhibiting the activation of neutrophil NSP enzymes. It is clinically intended to be used for the treatment of lower respiratory tract diseases caused by bronchiectasis and acute lung injury/acute respiratory distress syndrome. The drug has completed phase I clinical trials in Australia and China, and now the phase II clinical trials of the project have completed the enrollment and administration of the first subject, and the project is progressing smoothly.

* CSL 787: CSL Behring

CSL 787, is a human plasma-derived immunoglobulin for administration via a nebulizer for the potential prevention of chronic respiratory tract infections and progression of chronic lung disease such as Noncystic fibrosis bronchiectasis (NCFB). Currently, the drug is being developed in the Phase I stage of Clinical trial evaluation for the treatment of Noncystic fibrosis bronchiectasis.

The Non Cystic Fibrosis Bronchiectasis Pipeline Report provides insights into

* The report provides detailed insights about companies that are developing therapies for the treatment of Non Cystic Fibrosis Bronchiectasis with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Non Cystic Fibrosis Bronchiectasis Treatment.
* Non Cystic Fibrosis Bronchiectasis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Non Cystic Fibrosis Bronchiectasis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Non Cystic Fibrosis Bronchiectasis market.

Learn more about Non Cystic Fibrosis Bronchiectasis Drugs opportunities in our groundbreaking Non Cystic Fibrosis Bronchiectasis research and development projects @ Non Cystic Fibrosis Bronchiectasis Unmet Needs [https://www.delveinsight.com/sample-request/non-cystic-fibrosis-bronchiectasis-ncfb-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Non Cystic Fibrosis Bronchiectasis Companies

Zambon SpA, AstraZeneca, Insmed Incorporated, NovaBiotics, Haisco Pharmaceutical Group, Armata Pharmaceuticals, Chiesi Farmaceutici, CSL Behring and others.

Noncystic fibrosis bronchiectasis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

* Intravenous
* Subcutaneous
* Oral
* Intramuscular

Non Cystic Fibrosis Bronchiectasis Products have been categorized under various Molecule types such as

* Monoclonal antibody
* Small molecule
* Peptide

Stay informed about how we're transforming the future of Respiratory Disease @ Non Cystic Fibrosis Bronchiectasis Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/non-cystic-fibrosis-bronchiectasis-ncfb-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Non Cystic Fibrosis Bronchiectasis Pipeline Report

* Coverage- Global
* Non Cystic Fibrosis Bronchiectasis Companies- Zambon SpA, AstraZeneca, Insmed Incorporated, NovaBiotics, Haisco Pharmaceutical Group, Armata Pharmaceuticals, Chiesi Farmaceutici, CSL Behring and others.
* Non Cystic Fibrosis Bronchiectasis Pipeline Therapies- Nebulized Ensifentrine Suspension; 3 mg, HSK31858, ARINA-1, Brensocatib 10 mg, RESP302, BAY85-8501 and others.
* Non Cystic Fibrosis Bronchiectasis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Non Cystic Fibrosis Bronchiectasis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Non Cystic Fibrosis Bronchiectasis Pipeline on our website @ Non Cystic Fibrosis Bronchiectasis Emerging Drugs and Companies [https://www.delveinsight.com/sample-request/non-cystic-fibrosis-bronchiectasis-ncfb-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

* Introduction
* Executive Summary
* Noncystic fibrosis bronchiectasis: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Noncystic fibrosis bronchiectasis- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Brensocatib: Insmed Incorporated
* Mid Stage Products (Phase II)
* HSK31858: Haisco Pharmaceutical Group Co., Ltd.
* Early Stage Products (Phase I)
* CSL 787: CSL Behring
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Inactive Products
* Noncystic fibrosis bronchiectasis Key Companies
* Noncystic fibrosis bronchiectasis Key Products
* Noncystic fibrosis bronchiectasis- Unmet Needs
* Noncystic fibrosis bronchiectasis- Market Drivers and Barriers
* Noncystic fibrosis bronchiectasis- Future Perspectives and Conclusion
* Noncystic fibrosis bronchiectasis Analyst Views
* Noncystic fibrosis bronchiectasis Key Companies
* 23. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=non-cystic-fibrosis-bronchiectasis-pipeline-outlook-2025-clinical-trial-studies-ema-pdma-fda-approvals-moa-roa-nda-ind-and-companies]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/non-cystic-fibrosis-bronchiectasis-ncfb-pipeline-insight

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.